PJSC Borschahivsky Chemical Pharmaceutical Plant (Kyiv) increased its net profit 123.77% in 2019 compared to UAH 194.137 million in 2018.
According to the agenda of the shareholders’ annual meeting scheduled for April 22 in the information disclosure system of the National Securities and Stock Market Commission, the total receivables of the company amounted to UAH 327.414 million.
The company’s assets increased by 7.78%, to UAH 1.925 billion, net worth by 11.7%, to UAH 1.62 billion for the year.
According to the results of 2018, the plant reduced its net profit by 16.96%, compared to UAH 86.758 million in 2017.
PJSC Borschahivsky Chemical Pharmaceutical Plant is among the top 20 largest pharmaceutical manufacturers in Ukraine. It is a member of the Association of Manufacturers of Medications of Ukraine (AMMU).
The “one face to the customer” approach in customs would allow speeding up exports by Ukrainian pharmaceutical manufacturers, Commercial Director of PJSC Research and Industrial Center Borschahivka chemical and pharmaceutical plant Yevhen Sova has said. “The “one face to the customer” approach is intended to significantly facilitate the customs clearing and declaration of goods. We, for our part, are actively expanding and developing exports. The plant’s products are presented in 19 countries, and the share of exports is over 12%. We understand all benefits that the initiative could bring. In particular, this would allow supplying medicines more quickly and with smaller expenses,” he told Interfax-Ukraine.
At the same time, commenting on the completion of the transition period for the introduction of the updated order of information exchange at the Ukrainian customs using the “one face to the customer” approach, Sova said that “as for any innovation at the state level, it takes time to tune the work, identify and eliminate possible inconsistencies.” “This is a natural process,” he said.
At the same time Sova said that the state should ensure the competent implementation of the “one face to the customer” approach and also provide for clear rules and instructions that will allow fully implementing the changes, monitor the quality of their implementation and guarantee the expected result, namely, to simplify the mechanism of entering foreign markets for Ukrainian products.
It will be necessary to create infrastructure for vaccine production in Ukraine from scratch, while the state support program could contribute to this, Commercial Director of PJSC Borschahivsky Chemical and Pharmaceutical Plant Yevhen Sova believes. “Today it will be necessary to create infrastructure for vaccine production in Ukraine virtually from scratch. This is quite a long process, because we are talking about the construction of new workshops, the launch of additional production lines, passage of audits and confirmation of quality according to the standards,” he told Interfax-Ukraine.
At the same time, the expert noted that “Ukrainian pharmaceutical manufacturers can implement this.” “The technical equipment of domestic companies as a whole allows building new necessary infrastructure, paying special attention to the sites of quality control,” he said.
According to the expert, the state support program can become an impetus for domestic pharmaceutical producers and a signal for starting work on the organization of such production. “Such a program will contribute to the process as much as possible. It can include public-private partnership, tax-exempt status, simplified inspection procedures and other options, including subsidies,” he said.